文献速递造血干细胞移植与细胞治疗

优化成人恶性血液病双份脐血移植的移植物选择

Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性分析纳入1375例接受双份无关脐血移植的成人恶性血液病患者,评估移植物选择标准对结局的影响。结果显示,冻存总核细胞剂量≤3.5×10^7/kg、HLA错配≥2个及ABO不相合是总生存的独立危险因素;优势脐血CD34+细胞≥0.7×10^5/kg与更好的总生存相关。数据支持选择HLA匹配良好、每份脐血冻存TNC>3.5×10^7/kg且CD34+≥0.7×10^5/kg的移植物。

要点

  • 双份脐血移植应选择HLA错配0-1个的脐血单位。
  • 每份脐血冻存TNC应>3.5×10^7/kg,CD34+应≥0.7×10^5/kg。
  • 避免ABO主侧/次侧不相合可改善总生存。

核心结论

  • 双份脐血移植选择HLA匹配良好、每份冻存TNC>3.5×10^7/kg且CD34+≥0.7×10^5/kg的脐血单位可改善结局。

研究设计与样本

  • 回顾性分析1375例接受双份无关脐血移植的成人恶性血液病患者,评估移植物选择标准与移植结局的关系。

关键数值与推荐

  • 推荐选择HLA错配0-1个的脐血单位。
  • 推荐每份脐血冻存TNC>3.5×10^7/kg。
  • 推荐优势脐血CD34+细胞剂量≥0.7×10^5/kg。

临床怎么用

  • 成人双份脐血移植选移植物时,应优先考虑HLA匹配度、TNC剂量和CD34+剂量。
  • 尽量避免选择ABO主侧或次侧不相合的脐血单位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Double-unit unrelated cord blood transplantation (DUCBT) is an option in patients for whom a single unit is not sufficient to provide an adequate number of cells. As current guidelines on UCB unit selection are mainly based on single-unit UCB data, we performed a retrospective analysis of 1375 adult recipients of DUCBT for hematologic malignancies to determine optimal criteria for graft selection. Cryopreserved total nucleated cells (TNCs; ≤3.5 vs >3.5 × 107/kg: hazard ratio [HR], 1.53; 30% vs 45%; P = .01), number of HLA mismatches (≥2 vs 0-1: HR, 1.28; 42% vs 48%; P = .01), and ABO compatibility (minor/major ABO incompatibility vs compatibility: HR, 1.28; P = .04) were independent risk factors for OS. Cryopreserved CD34+ cell dose ≥0.7 × 105/kg in the winning UCB was associated with improved OS (HR, 1.34; P = .03). Low TNC (≤3.5 × 107/kg) and CD34+ (≤1.4 × 105/kg) cell doses were related to decreased neutrophil recovery (HR, 0.65 [P = .01] and HR, 0.81 [P = .01], respectively). DUCBT recipients with ≥2 HLA mismatches had a higher incidence of grade II-IV and III-IV acute graft-versus-host disease (HR, 1.26 [P = .03] and 1.59 [P = .02], respectively). Low TNC dose (HR, 1.57; P = .02) and receiving UCB with ≥2 HLA mismatches (HR, 1.35; P = .03) were associated with increased transplant-related mortality. Our data support selecting adequately HLA-matched UCB units with a double-unit cryopreserved TNC dose >3.5 × 107/kg and CD34+ cell dose of ≥0.7 × 105/kg per unit in DUCBT candidates.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Fatobene G, Volt F, Moreira F, et al. Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases. Blood Adv. 2020. PMID: 33351128. doi:10.1182/bloodadvances.2020002258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。